Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-05-09
2006-05-09
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S144100, C424S154100, C424S173100, C424S810000, C530S868000
Reexamination Certificate
active
07041289
ABSTRACT:
A method of treating spontaneous and ongoing auto-immune diseases in mammals, comprising administering to a mammal, in need of such a treatment, a therapeutically effective amount of one or more non mitogenic anti-CD3 active principles to achieve permanent disease remission through the induction of antigen-specific unresponsiveness, i.e. immune tolerance.
REFERENCES:
Racadot, E et al. Clinical Immunotherapy. 1(3):199-208, May 1994.
Gussow et al. Methods in Enzymology. 203:99-121, 1991.
Beers et al (Eds.), The Merck Manual, Seventeenth Edition, Merck Research Laboratories, 1999, pp. 816-818.
Chatenoud et al., “CD3 Antibody-Induced Dominant Self Tolerance in Overtly Diabetic NOD Mice”, The Journal of Immunology, The American Association for Immunologists, pp. 2947-2954 (1997).
Hirsch et al., “Anti-CD3 F(ab′)2Fragments are Immunosuppressive in Vivo Without Evoking Either the Strong Humoral Response or Morbidity Associated with Whole mAb”Transplantation49:1117-1123 (1990).
Hirsch et al., “Differential T Cell Hyporesponsiveness Induced by In Vivo Administration of Intact or F(ab′)2Fragments of Anti-CD3 Monoclonal Antibody”The Journal of Immunology147:2088-2093 (1991).
Herold et al., Prevention of Autoimmune Diabetes with Nonactivating Anti-CD3 Monoclonal AntibodyDiabetes41:385-391 (1992).
Hughes et al., “Induction of Helper Cell Hyporesponsiveness in an Experimenthal Model of Autoimmunity by Using Nonmitogenic Anti-CD3 Monoclonal Antibody”J. Immunol.153(7):3319-3325 (1994).
Chatenoud et al., “Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice”Proc. Natl. Acad. Sci. USA91:123:127 (1994).
Johnson et al., “Use of Anti-CD3ε F(ab′)2Fragments In Vivo to Modulate Graft-Versus-Host Disease Without Loss of Graft-Versus-Leukemia Reactivity After MHC-Matched Bone Marrow Transplantation,”J. Immunol.154(10):5542-5554 (1995).
Chatenoud, et al., “Monoclonal Antibodies to CD3 Restore Self Tolerance in Overtly Diabetic NOD Mice: Both Mitogenic and Non-Mitogenic Antibodies Afford Tolerance,”Autoimmunity, 21:72, Abstract A276 (1995).
Bach Jean-Francois
Chatenoud Lucienne
Institut National de la Sante et de la Recherche Medicale (INSER
Lillie Raymond J.
Olstein Elliot M.
Saunders David
LandOfFree
Method for treating established spontaneous auto-immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating established spontaneous auto-immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating established spontaneous auto-immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3539261